Subjects with resected adenocarcinoma or squamous cell carcinoma esophageal or gastroesophageal junction cancer
Conditions
Brief summary
Disease-free survival is the primary endpoint of this study. Disease-free survival is the time between randomization date and first date of recurrence or death, whichever occurs first.
Detailed description
Overall survival and overall survival rates are secondary endpoints. -Overall Survival is time between the date of randomization and the date of death. For subjects without documentation of death, OS will be censored on the last date the subject was known to be alive. -The overall survival rate at 1, 2, and 3 years is defined as the probability that a subject is alive at 1, 2, and 3 years, respectively, following randomization.
Interventions
DRUGPlacebo for BMS-936558
DRUGOPDIVO 10 mg/mL concentrate for solution for infusion.
Sponsors
Bristol Myers Squibb International Corporation
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease-free survival is the primary endpoint of this study. Disease-free survival is the time between randomization date and first date of recurrence or death, whichever occurs first. | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival and overall survival rates are secondary endpoints. -Overall Survival is time between the date of randomization and the date of death. For subjects without documentation of death, OS will be censored on the last date the subject was known to be alive. -The overall survival rate at 1, 2, and 3 years is defined as the probability that a subject is alive at 1, 2, and 3 years, respectively, following randomization. | — |
Countries
Belgium, Czechia, Denmark, France, Germany, Ireland, Netherlands, Poland, Romania, Spain
Outcome results
None listed